Meeting
2015 ASCO Annual Meeting
A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma.
Authors
Alba Ariela Brandes
Department of Medical Oncology, Azienda USL, Bologna, Italy
Alba Ariela Brandes , Antoine F Carpentier , Santosh Kesari , Juan Sepulveda , Helen Wheeler , Olivier L. Chinot , Lawrence Cher , Joachim Peter Steinbach , Pol Specenier , Ann Cleverly , Claire Smith , Ivelina Gueorguieva , Susan C. Guba , Durisala Desaiah , Michael M. F. Lahn , Wolfgang Wick
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01582269
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2014)
DOI
10.1200/jco.2015.33.15_suppl.2014
Abstract #
2014
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without EGFR-amplified recurrent glioblastoma.
First Author: Yoshitaka Narita
Poster
2016 ASCO Annual Meeting
Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.
First Author: Wolfgang Wick
Poster
2022 ASCO Annual Meeting
Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (BBB), for the treatment of recurrent glioblastoma multiforme (GBM) after first-line therapy.
First Author: Sandra Silberman
Poster
2022 ASCO Annual Meeting
A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma.
First Author: Masamichi Takahashi